Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Nasopharyngeal Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Thyroid cancer, follicular 1Thyroid cancer, Hurthle cell 1Thyroid Cancer, Papillary 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma 1Refractory or Recurrent Solid Tumor 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Unknown Primary 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Mesothelioma 1Locally Advanced Pancreatic Adenocarcinoma 1Leukemia, Myelomonocytic, Chronic 1Hemangiosarcoma 1Glioblastoma 1Fibrolamellar hepatocellular carcinoma 1Endometrial Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1

Interventions

pembrolizumab 2Pemetrexed 2Docetaxel 2Carboplatin 2Bevacizumab 2trifluridine tipiracil drug combination 1trametinib 1spartalizumab 1sotorasib 1sintilimab 1palbociclib 1netrin-1 inhibitor NP137 1atezolizumab 1Panitumumab 1Paclitaxel 1Oxaliplatin 1Leucovorin 1Irinotecan 1Injections 1Fluorouracil 1Everolimus 1Drug Therapy 1Cetuximab 1Afatinib 1ASP1570 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Advanced Solid Tumors × spartalizumab × Clear all
NCT04058756 2025-10-07

Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

Novartis

Phase 1 Active not recruiting
120 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡